Rare diseases
Investigational molecules
Locations
Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors
BelgiumStudy of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
AustriaStudy of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
AustriaStudy of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation
FranceStudy of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
FranceStudy of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer
BelgiumStudy Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
AustriaStudy of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy
AustriaStudy of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
CroatiaStudy of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
